Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company that specializes in the development of novel therapeutics for diseases affecting the vasculature, soft tissue, and skeleton. The company is currently focused on an enzyme replacement therapy, INZ-701, which aims to address pathologic mineralization and intimal proliferation that can lead to severe health issues.
INZ-701 is in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. The company’s mission is to provide innovative solutions to rare disease patients who have limited options for treatment.
Doug Treco, Ph.D., CEO and Chairman of Inozyme, will be participating in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024. The chat will take place from 6:40-7:10pm ET / 3:40-4:10pm PT and will be accessible through the Investor Relations section of Inozyme’s website under events. A replay of the event will also be available for a limited time.
For more information about Inozyme Pharma Inc., visit their website at
Media inquiries can be directed to Matt Pera at SmithSolve by calling (973) 886-9150 or emailing matt.pera@smithsolve.com if you have any further questions regarding this upcoming event with Doug Treco or want more information about Inozyme Pharma Inc.’s ongoing work in developing new treatments for rare diseases affecting these areas of human anatomy.